Ozempic and Heart Health: The Cardiovascular Benefits Explained

Most people start Ozempic to lose weight. But somewhere along the way, researchers noticed something unexpected: patients taking semaglutide were also having fewer heart attacks and strokes. That finding changed how cardiologists think about this drug, and it’s worth understanding what’s actually happening, why it matters, and who stands to benefit most.

What the Research Shows

The landmark evidence comes from the SUSTAIN-6 trial, a cardiovascular outcomes study that followed over 3,200 people with type 2 diabetes and high cardiovascular risk for roughly two years. Published in the New England Journal of Medicine in 2016, the trial found that patients taking semaglutide had a significantly lower rate of major adverse cardiovascular events (MACE), a category that includes heart attack, stroke, and cardiovascular death, compared to those on placebo.

The reduction was meaningful. Semaglutide cut the risk of MACE by approximately 26% compared to placebo. That’s not a marginal finding. For a medication that was originally developed to manage blood sugar, a cardiovascular benefit of that magnitude got serious attention from the cardiology community.

Then came the SELECT trial, which expanded the picture considerably. Published in 2023, SELECT specifically enrolled people who were overweight or obese but did not have diabetes, making it the first major cardiovascular outcomes trial for a GLP-1 medication in a non-diabetic population. The results showed a 20% reduction in major cardiovascular events in the semaglutide group compared to placebo over a follow-up period of about five years. You can read more about what the SELECT trial means for patients at The SELECT Trial: What It Means for Ozempic Patients.

How Semaglutide Protects the Heart

Weight loss alone explains some of the benefit. Carrying excess body weight strains the heart, raises blood pressure, worsens cholesterol profiles, and drives inflammation, all of which increase cardiovascular risk. When patients lose 10–15% of their body weight on semaglutide, those risk factors improve across the board.

But weight loss isn’t the whole story. Researchers believe semaglutide also has direct cardiovascular effects that go beyond what the scale shows.

Blood Pressure Reduction

GLP-1 receptors are found in blood vessels and the kidneys, and activating them appears to have a modest but consistent blood pressure-lowering effect. In clinical trials, semaglutide users showed meaningful reductions in systolic blood pressure, which matters because even small, sustained drops in blood pressure reduce the lifetime risk of heart attack and stroke. For a deeper look at this mechanism, How GLP-1 Medications Affect Blood Pressure Over Time walks through the evidence.

Cholesterol and Triglycerides

Semaglutide consistently improves lipid panels in clinical trials. LDL (“bad”) cholesterol tends to decrease, HDL (“good”) cholesterol tends to increase, and triglycerides often drop significantly. These aren’t dramatic shifts on their own, but combined with weight loss and blood pressure improvements, they contribute to a meaningfully lower cardiovascular risk profile over time. If you have elevated triglycerides specifically, High Triglycerides and GLP-1 Medications covers what to expect.

Anti-Inflammatory Effects

Chronic low-grade inflammation is a major driver of atherosclerosis, the buildup of plaque in artery walls that leads to heart attacks and strokes. Research suggests semaglutide may reduce markers of systemic inflammation, including C-reactive protein (CRP). Whether this is primarily a consequence of weight loss or a direct drug effect is still being studied, but the pattern appears consistently across trials.

Direct Cardiac Effects

Some researchers believe GLP-1 receptors in the heart itself may play a role. Animal studies have suggested protective effects on heart muscle cells, and human data shows improvements in certain cardiac function markers. This remains an active area of investigation, but the hypothesis that semaglutide has mechanisms of cardiac protection beyond metabolic improvement is gaining traction.

Who Benefits Most

The cardiovascular benefits of Ozempic are most clearly established in people who already have elevated cardiovascular risk. That includes:

People with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), people with type 2 diabetes, people with obesity-related conditions like high blood pressure, high cholesterol, or sleep apnea, and people with metabolic syndrome.

Consider this scenario: a 58-year-old patient with a prior heart attack, type 2 diabetes, and a BMI of 34 starts semaglutide primarily to manage blood sugar and lose weight. Over two years, they lose 18 pounds, their blood pressure drops, their LDL improves, and their cardiologist notes their inflammatory markers have decreased. The weight loss helped, but the totality of metabolic improvement likely contributed to lower cardiovascular risk than weight loss alone would explain.

For people without established cardiovascular disease or diabetes, the SELECT trial suggests benefit still exists for those who are overweight or obese, though the absolute risk reduction in a lower-risk population is naturally smaller.

What This Means in Practice

The FDA approved Ozempic (semaglutide 1 mg) in 2021 to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established heart disease. That’s a formal cardiovascular indication, not just a side benefit. For patients who qualify, this means semaglutide isn’t just about losing weight. It’s a medication with documented, trial-proven cardiovascular protection.

For those using semaglutide primarily for weight loss, the heart health data adds another layer of benefit. Losing weight with semaglutide isn’t just cosmetic. It’s metabolically and cardiovascularly meaningful in ways that traditional dieting rarely achieves.

One important caveat: semaglutide is not appropriate for everyone with heart disease. People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 should avoid GLP-1 medications. Those with certain gastrointestinal conditions or pancreatitis history also need careful evaluation. A provider review of your full medical history is essential before starting.

Ozempic vs. Other GLP-1 Medications for Heart Health

Semaglutide has the strongest cardiovascular outcomes data among the GLP-1 class, but it’s not the only option. Tirzepatide, the active ingredient in Mounjaro and Zepbound, is currently under investigation in large cardiovascular outcomes trials. Early data from the SURMOUNT program is promising, but the definitive cardiovascular outcomes data that semaglutide has accumulated over years doesn’t yet exist for tirzepatide at the same scale.

Liraglutide (Victoza) has its own cardiovascular outcomes trial showing benefit in diabetes patients, making it the predecessor to semaglutide’s data. But semaglutide’s effect sizes were larger, which is part of why it’s become the reference standard in the conversation about GLP-1 and heart health.

Getting Started

If you have cardiovascular risk factors or established heart disease and you’re considering semaglutide, the combination of weight loss support and direct cardiovascular protection makes it one of the more compelling medications available right now. The conversation with your provider should include your full cardiac history, current medications, and your specific risk profile.

Start your assessment with TrimRx to see if you’re a candidate and connect with a clinician who can evaluate your situation.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.